Related Experiment Video
Updated: Nov 30, 2025
10:40
Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods
Published on: December 21, 2019
26.3K
Copper(II) Inhibition of the SARS-CoV-2 Main Protease
Roberto A Garza-López1, John J Kozak2, Harry B Gray3
1Department of Chemistry and Seaver Chemistry Laboratory, Pomona College, Claremont, CA 91711.
Chemrxiv : the Preprint Server for Chemistry
|November 17, 2020
Summary
Copper(II) chelates can disable the coronavirus main protease (Mpro) by binding to key active-site residues. This binding forms stable structures that inhibit Mpro function, offering a potential therapeutic strategy.
Area of Science:
- Biochemistry
- Structural Biology
- Drug Discovery
Background:
- The coronavirus main protease (Mpro) is a critical enzyme for viral replication.
- Previous studies identified cobalt(III) cations as potential inhibitors of Mpro by binding to histidine and cysteine residues.
Approach:
- This study investigated the interaction of copper(II) chelates with the Mpro active site.
- Computational docking was employed to model the binding of Cu(II) to HIS 41 and CYS 145.
- Structural stability of the docked complexes was analyzed.
Key Points:
- Copper(II) chelates form stable docked structures within the Mpro active site.
- Cu(II) readily binds to the CYS 145 thiolate residue.
- This interaction is predicted to be lethal to Mpro enzyme activity.
Conclusions:
- Copper(II) chelates represent a promising class of compounds for Mpro inhibition.
- Targeting Mpro active-site residues with metal chelates offers a novel therapeutic avenue.
- Further research into Cu(II) chelate derivatives could lead to effective antiviral agents.
Related Concept Videos
01:30Enzyme Inhibition
89.2K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
89.2K
02:34Inhibition of Cdk Activity
5.4K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K